Mark B. Booth

• Development of a strategic brand plan development and planning, overseeing commercial operations, field force structure & deployment, supply chain packaging, pricing research, incentive compensation design, revenue forecasting, account profiling, and driving US product label creation
• Drove the pre-launch commercialization strategy by conducting in-depth competitor analyses, integrating KOL feedback, and leveraging patient and advocacy insights to define the value proposition, market positioning, and patient journey
• Responsible and accountable for short- and long-term strategic initiatives spanning brand marketing, market research, market access, supply chain, finance, and corporate communications
• Leadership, driving a 30% improvement in market readiness and supporting a successful product launch within 12 months
• Developed and executed a pre-launch disease education strategy, increasing disease awareness by 62% within the targeted population and acquiring over 2,600 patient registrations (33% of the target population)
• Optimized enterprise data systems to support strategic decision-making, resulting in a 20% boost in pre-launch efficiency across the top 150 key accounts
• Ensured strategic and tactical plans met compliance, regulatory, and company policies, including operating expenses budget guidelines
• Led cross-functional collaboration between medical affairs, market access, and manufacturing teams to develop limited distribution plans and implement patient hub services
• P&L responsibility
• Designed and guided the execution of market access, reimbursement & pricing strategy
• Oversaw the design, hiring, training, and certification of the sales force and other customer-facing roles

• Tasked to strategically analyze and evaluate all internal data assets to identify strengths, weaknesses, opportunities, and threats, optimize existing product offerings, retire unprofitable products, and develop innovative data solutions for pharmaceutical manufacturers
• Led the internal data interrogation and SWOT evaluation for go-no-go product syndication
• Led, developed, and deployed a global social KOL platform product for pharmaceutical manufacturers, contributing 2M in recurring revenue
• Created an integrated oncology report for commercialization, leveraging claims, EMR, and qualitative insights
• Leveraged existing and newly developed product offerings to inform $5.4M in bespoke research
• Delivered exceptional customer service by implementing best practices and fostering a culture of accountability within the organization.
• Developed and executed strategic initiatives to drive business growth, resulting in higher revenues and market share expansion.
• Championed innovation by encouraging cross-functional teams to pursue creative solutions to complex challenges.

• Spearheaded a global oncology business strategy across four vertical business units: Clinical and Scientific Assessment, Market Insights, Health Outcomes, and Client Consulting
• Executed tactical plans to enhance client satisfaction and drive business growth with existing and new untapped business prospects
• Proven record of building a high-performing organization; demonstrated success in leading Sales and Marketing organizations and building critical capabilities in a complex selling environment
• Directed commercial market research and consulting engagements within oncology and specialty therapeutic areas, such as Demand Forecast, Pipeline prioritization, ATUs, Asset Evaluation, TPP Evaluation, Segmentation, and Outcomes Research
• Drove syndicated products' YOY annual revenue by double digits and achieved more than 20M in annual revenue via strong client relationships, client product expansion, and new business opportunities
• Cultivated strong relationships with key stakeholders, including customers, vendors, regulators, and community leaders to promote collaboration and long-term success.
• Led cross-functional teams for the successful completion of major projects, resulting in increased efficiency and client satisfaction.

Responsible for developing and executing marketing strategies specifically for the US market, including managing the US marketing team and overseeing all aspects, from driving brand awareness to sales generation

• Led development and implementation of promotional platforms, including messaging, segmentation, market research, and unbranded and branded websites, leading to 28M in launch revenue.
• Developed customer Marketing team to understand and determine the needs of top institutions, key opinion leaders, and competitor landscape.
• Chief architect for direct-to-consumer telemedicine strategy by establishing innovative sales channel partnerships with“ UpScript” & “KwickMed” for direct-to-consumer patient solutions
• Worked effectively in fast-paced environments.

• Expanded syndicated assets with double-digit year-over-year growth in both big, mid-sized, and emerging pharma companies to more than 30M in revenue
• Drove innovation and expansion of oncology product offerings for CancerMPact and co-developed a syndicated pharma clinical insights platform
• Co-led strategy development for the new syndicated service “CancerLandscape,” including marketing promotions, tactical execution, and software enhancement
• Alliance Partner-Cota Healthcare and Neogenomics; led collaboration, drafted term sheet, and brokered data partnership.
• Led cross-functional teams to complete major projects successfully, resulting in increased efficiency and client satisfaction.

• Developed and executed US brand strategy and market segmentation for Keytruda/pembrolizumab
• Constructed US-Brand plan including market map, customer segmentation, product benefit ladder, positioning statement, buying process, and competitive market mix
• Developed and facilitated KOL identification, advisory boards, and engagement plans
• Co-led new “Merck Oncology” identity project and oversaw biomarker and lab strategy development
• Developed comprehensive marketing plans in alignment with overall business goals and objectives.
• Oversaw the creation of compelling marketing materials, including brochures, presentations, and social media content.

• Developed and executed a comprehensive global launch strategy for Vintafolide and Etarfolatide companion diagnostic, resulting in planned market entry across20+ countries within18 months
• Responsible for global brand strategy, launch planning, and lifecycle management for Vintafolide/VYNFINIT indicated for platinum-resistant ovarian cancer, including a companion diagnostic
• Established strategic partnerships with key opinion leaders to enhance understanding of market insights and product adoption across multiple geographies
• Oversaw country and region-based launch planning, including pricing models and market access tactics and execution of European Early Access Programs
• Collaborated with cross-functional teams to ensure consistent messaging across all marketing channels.
• Developed insightful analytics reports for senior leadership to support data-driven decision making in marketing strategy development.
• Secured strategic partnerships with complementary brands for mutually beneficial co-marketing efforts, enhancing overall reach and visibility.

• Managed Global sales and marketing for Emend and Onicet/Aloxi, including profit and loss ownership, implementation of global pricing recommendations, and brand strategy
• Global P&L responsibility and ownership of global pricing recommendations and brand strategy
• Grew Emend annual revenue to $280M, exceeding year-over-year Ex-US growth by 121% and 114% sales growth for Onicit in LATAM markets
• Oversaw brand strategy evolution, promotional content development, and global KOL management and strategy
• Chaired multi-disciplinary rest of world brand strategy teams, including legal, medical, regulatory, promotions, sales, and finance
• Executed pre-launch activities & launch of Emend Single Dose IV in Spain, Italy, UK, and Korea
• Implemented three global, nurse-directed disease awareness programs designed to differentiate Emend and encourage earlier use via active communication channels (digital & call center-driven)

• Managed a portfolio of oncology products, including Emend and Temodar, driving annual sales growth of 18% across the New England Region
• Received multiple accolades, including the 2009 Director's Award for exceptional team performance and the 2007 Master's Premiere Award for leading the #1 region in sales
• Enhanced customer satisfaction by streamlining communication channels and improving response times.
• Developed innovative solutions to complex problems, resulting in improved organizational performance.
• Assisted in employee appraisals, promotions and terminations based on performance reviews.
• Achieved company growth by implementing strategic marketing plans and business development initiatives.
• Interviewed, recruited and trained new onboarding candidates.

• Directed teams of 10–14 specialists across key territories, consistently exceeding sales targets by 134% and receiving the 2005 Directors Award for top district performance
• Led the regional launch of Vytorin, increasing early market penetration by 25% through innovative sales strategies and team collaboration
• Increased sales revenue by developing and implementing effective sales strategies.
• Led a successful sales team by providing motivational coaching and performance-based incentives.
• Boston & Southern New England Regions

• Led product education and skill-based training programs for200+ sales representatives, improving product knowledge and increasing sales performance by 15%
• Played a critical role in the Vioxx and Vytorin launch campaigns, achieving rapid adoption in key territories nationwide
• Arthritis and Analgesics lead national trainer

• Consistently surpassed annual sales targets by120%, earning "Vice President's Club" recognition for elite performance
• Promoted to Senior Sales Representative within two years for driving client acquisition and expanding territory revenue by25%

• Achieved #1 district ranking in sales by growing Codimal and Niferex adoption by 40% and securing key contracts with pharmacy benefit managers
• Expanded customer base by 20%, contributing to sustained regional market dominance